IL304567B2 - Methods of detecting oncogenic pik3ca - Google Patents
Methods of detecting oncogenic pik3caInfo
- Publication number
- IL304567B2 IL304567B2 IL304567A IL30456723A IL304567B2 IL 304567 B2 IL304567 B2 IL 304567B2 IL 304567 A IL304567 A IL 304567A IL 30456723 A IL30456723 A IL 30456723A IL 304567 B2 IL304567 B2 IL 304567B2
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- nucleic acid
- acid molecule
- cytosine
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 84
- 231100000590 oncogenic Toxicity 0.000 title claims description 22
- 230000002246 oncogenic effect Effects 0.000 title claims description 22
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 138
- 102000039446 nucleic acids Human genes 0.000 claims description 106
- 108020004707 nucleic acids Proteins 0.000 claims description 106
- 150000007523 nucleic acids Chemical class 0.000 claims description 106
- 206010028980 Neoplasm Diseases 0.000 claims description 81
- 229940104302 cytosine Drugs 0.000 claims description 69
- 201000011510 cancer Diseases 0.000 claims description 66
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims description 63
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 55
- 239000003112 inhibitor Substances 0.000 claims description 49
- 210000000349 chromosome Anatomy 0.000 claims description 45
- 101100520033 Dictyostelium discoideum pikC gene Proteins 0.000 claims description 38
- 239000002773 nucleotide Substances 0.000 claims description 35
- 125000003729 nucleotide group Chemical group 0.000 claims description 35
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 28
- 108020004414 DNA Proteins 0.000 claims description 22
- 108020004999 messenger RNA Proteins 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 17
- 102000053602 DNA Human genes 0.000 claims description 15
- 101150063858 Pik3ca gene Proteins 0.000 claims description 15
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical group S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 229950010482 alpelisib Drugs 0.000 claims description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 230000003197 catalytic effect Effects 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 108010029485 Protein Isoforms Proteins 0.000 claims description 7
- 102000001708 Protein Isoforms Human genes 0.000 claims description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 238000011319 anticancer therapy Methods 0.000 claims description 6
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 108091000080 Phosphotransferase Proteins 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 208000024312 invasive carcinoma Diseases 0.000 claims description 5
- 238000011528 liquid biopsy Methods 0.000 claims description 5
- 102000020233 phosphotransferase Human genes 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 230000035772 mutation Effects 0.000 description 73
- 239000000523 sample Substances 0.000 description 29
- 239000000203 mixture Substances 0.000 description 17
- 239000012828 PI3K inhibitor Substances 0.000 description 13
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 13
- 108091007960 PI3Ks Proteins 0.000 description 8
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 8
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000004055 small Interfering RNA Substances 0.000 description 6
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000007730 Akt signaling Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- -1 Risovalisib Chemical compound 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- 108091008039 hormone receptors Proteins 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000007481 next generation sequencing Methods 0.000 description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- BLGWHBSBBJNKJO-UHFFFAOYSA-N serabelisib Chemical compound C=1C=C2OC(N)=NC2=CC=1C(=CN12)C=CC1=NC=C2C(=O)N1CCOCC1 BLGWHBSBBJNKJO-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 201000007983 brain glioma Diseases 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229950008344 serabelisib Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 201000003701 uterine corpus endometrial carcinoma Diseases 0.000 description 2
- STUWGJZDJHPWGZ-GFCCVEGCSA-N (2R)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@@H]1C(N)=O STUWGJZDJHPWGZ-GFCCVEGCSA-N 0.000 description 1
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 description 1
- SGEUNORSOZVTOL-CABZTGNLSA-N (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide Chemical compound FC([C@H]1N(C(OC1)=O)C=1N=C2N(CCOC3=C2C=CC(=C3)N[C@H](C(=O)N)C)C=1)F SGEUNORSOZVTOL-CABZTGNLSA-N 0.000 description 1
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 description 1
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 1
- RQPKSOWRJPRYCN-UHFFFAOYSA-N 3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)aniline Chemical compound NC1=CC=CC(C=2N=C3C4=CC=CN=C4OC3=C(N3CCOCC3)N=2)=C1 RQPKSOWRJPRYCN-UHFFFAOYSA-N 0.000 description 1
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 description 1
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 description 1
- LGWACEZVCMBSKW-UHFFFAOYSA-N 5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine Chemical compound CC1(C)OCCN(C2=N3)C1=NC2=C(N1CCOCC1)N=C3C1=CN=C(N)N=C1 LGWACEZVCMBSKW-UHFFFAOYSA-N 0.000 description 1
- JEGHXKRHKHPBJD-UHFFFAOYSA-N 5-(7-methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine Chemical compound CS(=O)(=O)N1CCC2=C1N=C(N1CCOCC1)N=C2C1=CN=C(N)N=C1 JEGHXKRHKHPBJD-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 108091007958 Class I PI3Ks Proteins 0.000 description 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010073073 Hepatobiliary cancer Diseases 0.000 description 1
- 101100190564 Homo sapiens PIK3CA gene Proteins 0.000 description 1
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 description 1
- 101000741885 Homo sapiens Protection of telomeres protein 1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012823 PI3K/mTOR inhibitor Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 101710125691 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 description 1
- 101710204747 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100038745 Protection of telomeres protein 1 Human genes 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Natural products C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229950009671 capivasertib Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229950002550 copanlisib Drugs 0.000 description 1
- PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000006974 gastroesophageal cancer Diseases 0.000 description 1
- 229950008209 gedatolisib Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000051957 human ERBB2 Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 229940071122 inavolisib Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000013546 insoluble monolayer Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229950006331 ipatasertib Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 229940069682 miransertib Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001222 nononcogenic Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940016672 paxalisib Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000003410 quininyl group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 102200085788 rs121913279 Human genes 0.000 description 1
- 102200085789 rs121913279 Human genes 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229950001269 taselisib Drugs 0.000 description 1
- 230000033863 telomere maintenance Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000037964 urogenital cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
METHODS OF DETECTING ONCOGENIC PIK3CA REFERENCE TO AN ELECTRONIC SEQUENCE LISTING id="p-1" id="p-1" id="p-1" id="p-1" id="p-1" id="p-1" id="p-1"
id="p-1"
[001] The contents of the electronic sequence listing (ONDP-RMT-P-001-IL.xml; Size: 369,781 bytes; and Date of Creation: July 18, 2023) is herein incorporated by reference in its entirety.
FIELD OF INVENTION id="p-2" id="p-2" id="p-2" id="p-2" id="p-2" id="p-2" id="p-2"
id="p-2"
[002] The present invention is in the field of cancer diagnostics.
BACKGROUND OF THE INVENTION id="p-3" id="p-3" id="p-3" id="p-3" id="p-3" id="p-3" id="p-3"
id="p-3"
[003] Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that are involved in multiple cellular functions such as proliferation, cell growth, differentiation, adhesion, motility, intracellular trafficking, and survival. PI3Ks contain a conserved core composed of a C2 domain, a kinase domain, and a helical domain. Based on their substrate specificities and structural characteristics, PI3Ks are classified into four main classes: I, II, III and IV. Class I PI3Ks are heterodimeric molecules composed of a regulatory and a catalytic subunit and are divided to IA and IB subsets. Class IA PI3Ks are composed of a p110 catalytic subunit and a shorter regulatory subunit, mainly p85. The p110 catalytic subunit is known to have three different isoforms designated p110α, 110β, or 110δ. These catalytic subunits are encoded by separate genes; PIK3CA, PIK3CB, and PIK3CD for p110α, p110β, and p110δ, respectively. id="p-4" id="p-4" id="p-4" id="p-4" id="p-4" id="p-4" id="p-4"
id="p-4"
[004] The signaling mediated by PI3Ks, the PI3K/AKT signaling pathway, is known to play a key role in the progression of variety of cancers by inducing metabolism, cell growth, proliferation, angiogenesis, and metastasis. In fact, activation of the PI3K/AKT pathway occurs in approximately 30–50% of human cancers and results in resistance to various anti-cancer therapies. id="p-5" id="p-5" id="p-5" id="p-5" id="p-5" id="p-5" id="p-5"
id="p-5"
[005] Mutations in exon-coding regions of the PIK3CA gene, which lead to an amino acid substitution and result in increased activity of the p110α catalytic subunit, have been previously reported in variety of cancers. PIK3CAE545K is an example for a hotspot mutation in the coding region of exon 9, which results in suppressed inhibition of p110α by the p85 regulatory subunit. Another mutation, PIK3CAH1047, is present in the coding region of exon 20, and leads to enhanced affinity between the p110α subunit and the lipid membrane. PIK3CAE542K is another known mutation with significant oncogenic potential associated with elevated catalytic activity of the p110α subunit. id="p-6" id="p-6" id="p-6" id="p-6" id="p-6" id="p-6" id="p-6"
id="p-6"
[006] The correlation between activated PI3K/AKT signaling pathway and tumor progression has led to the recognition of PI3Ks as therapeutic targets in cancer. Idelalisib (PIK3CD inhibitor) was the first FDA-approved PI3K inhibitor for treatment of blood cancer, initially used in clinical practice in 2014. Today there are dozens of PI3K inhibitors, many of which are currently employed in clinical trials evaluation. Based on their mode of action, PI3K inhibitors are subdivided into dual PI3K/mTOR inhibitors, targeting both PI3K and the serine–threonine kinase mTOR due to their structural homology, pan-PI3K inhibitors, and isoform-specific inhibitors. Among the isoform-specific inhibitors, Alpelisib (BYL719), FDA-approved for treatment of HR-positive and HER2/neu-negative breast cancer in combination with endocrine therapy, and Serabelisib (MLN1117), which is undergoing clinical trials for several types of cancers, are PIK3CA inhibitors that selectively inhibit the p110α catalytic subunit. id="p-7" id="p-7" id="p-7" id="p-7" id="p-7" id="p-7" id="p-7"
id="p-7"
[007] Noncoding mutations in deep introns of tumor suppressor genes (TSGs), such as the telomere maintenance gene, POT1, were reported to contribute to tumorigenesis, specifically in blood cancers. Interestingly, these reported intronic mutations were overrepresented in TSGs but not in oncogenes ("Jung H et al., Comprehensive characterization of intronic mis-splicing mutations in human cancers. Oncogene. 2021; 40:1347-1361", herein incorporated by reference in its entirety). id="p-8" id="p-8" id="p-8" id="p-8" id="p-8" id="p-8" id="p-8"
id="p-8"
[008] There is a need for new biomarkers that may assist in strategic decision making in cancer. Specifically, understanding mechanisms involved in the PI3K/AKT signaling pathway in cancer, that are not related to known amino acid substitution mutations, and that can serve as either diagnostic or prognostic tools, or to affect the selection of a PIK3 inhibitor drug as a cancer therapy, are of great need.
SUMMARY OF THE INVENTION id="p-9" id="p-9" id="p-9" id="p-9" id="p-9" id="p-9" id="p-9"
id="p-9"
[009] The present invention provides methods of detecting oncogenic phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), diagnosing cancer and determining suitability of a subject suffering from cancer to be treated with a PI3K inhibitor comprising detecting the presence of a cytosine at position 1792035on chromosome 3 of hg38. Nucleic acid molecules and kits that differentiate between a cytosine and a guanine at position 179203524 on chromosome 3 of hg38 are also provided. id="p-10" id="p-10" id="p-10" id="p-10" id="p-10" id="p-10" id="p-10"
id="p-10"
[010] According to a first aspect, there is provided a method of detecting oncogenic phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in a sample, the method comprising, receiving a sample comprising a nucleic acid molecule and detecting the presence of a cytosine at position 179203524 on chromosome 3 in the nucleic acid molecule wherein the position is with respect to human genome build hg38, wherein the presence of the cytosine indicates the presence of oncogenic PIK3CA, thereby detecting oncogenic PIK3CA. id="p-11" id="p-11" id="p-11" id="p-11" id="p-11" id="p-11" id="p-11"
id="p-11"
[011] According to another aspect, there is provided a method of diagnosing cancer in a subject, the method comprising receiving a sample from the subject, detecting the presence of a cytosine at position 179203524 on chromosome 3 in a nucleic acid molecule from the sample wherein the position is with respect to human genome build hg38, wherein the presence of the cytosine indicates the subject suffers from cancer, thereby diagnosing cancer in a subject. id="p-12" id="p-12" id="p-12" id="p-12" id="p-12" id="p-12" id="p-12"
id="p-12"
[012] According to another aspect, there is provided a method of selecting a subject suffering from cancer suitable for treatment with a phospatidylinositol-3 kinase (PI3K) inhibitor, the method comprising detecting the presence of a cytosine at position 1792035on chromosome 3 in a nucleic acid molecule derived from a cancer cell of the subject, wherein the position is with respect to human genome build hg38, thereby selecting a subject suffering from cancer suitable for treatment with a PIK3 inhibitor. id="p-13" id="p-13" id="p-13" id="p-13" id="p-13" id="p-13" id="p-13"
id="p-13"
[013] According to some embodiments, the nucleic acid molecule is a DNA molecule or a pre-mRNA molecule. id="p-14" id="p-14" id="p-14" id="p-14" id="p-14" id="p-14" id="p-14"
id="p-14"
[014] According to some embodiments, the DNA molecule comprises a PIK3CA genomic locus or the pre-mRNA comprises a PIK3CA transcript. id="p-15" id="p-15" id="p-15" id="p-15" id="p-15" id="p-15" id="p-15"
id="p-15"
[015] According to some embodiments, a PIK3CA gene and transcript comprises SEQ ID NO: 1 or 2 and wherein the cytosine is at position 55168 in the nucleotide sequence as set forth in SEQ ID NO: 1, or at position 54951 in the nucleotide sequence as set forth in SEQ ID NO: 2. id="p-16" id="p-16" id="p-16" id="p-16" id="p-16" id="p-16" id="p-16"
id="p-16"
[016] According to some embodiments, the cancer is selected from: breast cancer, lung cancer, uterine cancer, brain cancer, head and neck cancer, kidney cancer, and thyroid cancer. id="p-17" id="p-17" id="p-17" id="p-17" id="p-17" id="p-17" id="p-17"
id="p-17"
[017] According to some embodiments, the cancer is breast cancer or lung cancer. id="p-18" id="p-18" id="p-18" id="p-18" id="p-18" id="p-18" id="p-18"
id="p-18"
[018] According to some embodiments, the breast cancer is breast invasive carcinoma, and the lung cancer is lung squamous cell carcinoma. id="p-19" id="p-19" id="p-19" id="p-19" id="p-19" id="p-19" id="p-19"
id="p-19"
[019] According to some embodiments, the detecting the presence of a cytosine comprises amplifying the nucleic acid molecule with at least one primer specific to the cytosine at position 179203524, wherein the specific primer does not amplify a nucleic acid molecule with a guanine at position 179203524. id="p-20" id="p-20" id="p-20" id="p-20" id="p-20" id="p-20" id="p-20"
id="p-20"
[020] According to some embodiments, the detecting the presence of a cytosine comprises sequencing the nucleic acid molecule or an amplified copy thereof. id="p-21" id="p-21" id="p-21" id="p-21" id="p-21" id="p-21" id="p-21"
id="p-21"
[021] According to some embodiments, the method further comprises before the detecting receiving a sample comprising the nucleic acid molecule derived from a cancer cell of the subject. id="p-22" id="p-22" id="p-22" id="p-22" id="p-22" id="p-22" id="p-22"
id="p-22"
[022] According to some embodiments, the sample is a tumor sample comprising at least one cancerous cell or a liquid biopsy comprising at least one cell-free DNA molecule derived from a cancerous cell. id="p-23" id="p-23" id="p-23" id="p-23" id="p-23" id="p-23" id="p-23"
id="p-23"
[023] According to some embodiments, the method further comprises after the detecting administering to a subject diagnosed with cancer at least one anticancer therapy. id="p-24" id="p-24" id="p-24" id="p-24" id="p-24" id="p-24" id="p-24"
id="p-24"
[024] According to some embodiments, the method further comprises after the detecting administering to a suitable subject at least one PIK3 inhibitor. id="p-25" id="p-25" id="p-25" id="p-25" id="p-25" id="p-25" id="p-25"
id="p-25"
[025] According to some embodiments, the PIK3 inhibitor is an inhibitor of the catalytic subunit of PIK3 (P110). id="p-26" id="p-26" id="p-26" id="p-26" id="p-26" id="p-26" id="p-26"
id="p-26"
[026] According to some embodiments, the PIK3 inhibitor is a P110 specific inhibitor. id="p-27" id="p-27" id="p-27" id="p-27" id="p-27" id="p-27" id="p-27"
id="p-27"
[027] According to some embodiments, the P110 is P110 isoform alpha (P110α). id="p-28" id="p-28" id="p-28" id="p-28" id="p-28" id="p-28" id="p-28"
id="p-28"
[028] According to some embodiments, the PIK3 inhibitor is Alpelisib. id="p-29" id="p-29" id="p-29" id="p-29" id="p-29" id="p-29" id="p-29"
id="p-29"
[029] According to another aspect, there is provided a PIK3 inhibitor for use in treating cancer in a subject in need thereof, wherein the subject has been determined to comprise a cytosine at position 179203524 on chromosome 3, wherein the position is with respect to human genome build hg38. id="p-30" id="p-30" id="p-30" id="p-30" id="p-30" id="p-30" id="p-30"
id="p-30"
[030] According to some embodiments, the determining comprises receiving a sample from the subject comprising a nucleic acid molecule derived from a cancer cell of the subject and detecting the presence of the cytosine at position 179203524 on chromosome 3 in the nucleic acid molecule. id="p-31" id="p-31" id="p-31" id="p-31" id="p-31" id="p-31" id="p-31"
id="p-31"
[031] According to another aspect, there is provided a nucleic acid molecule that differentiates between a cytosine and a guanine at position 179203524 on chromosome 3, wherein the position is with respect to human genome build hg38. id="p-32" id="p-32" id="p-32" id="p-32" id="p-32" id="p-32" id="p-32"
id="p-32"
[032] According to some embodiments, the nucleic acid molecule does not bind to a nucleotide sequence as set forth in any one of SEQ ID NO: 1-3 and does bind to a nucleotide sequence as set forth in any one of SEQ ID NO: 4-6. id="p-33" id="p-33" id="p-33" id="p-33" id="p-33" id="p-33" id="p-33"
id="p-33"
[033] According to some embodiments, the nucleic acid molecule consists of not more than nucleotides. id="p-34" id="p-34" id="p-34" id="p-34" id="p-34" id="p-34" id="p-34"
id="p-34"
[034] According to some embodiments, the nucleic acid molecule is for use in performing a method of the invention. id="p-35" id="p-35" id="p-35" id="p-35" id="p-35" id="p-35" id="p-35"
id="p-35"
[035] According to another aspect, there is provided a kit comprising a nucleic acid molecule of the invention and at least one PIK3 inhibitor. id="p-36" id="p-36" id="p-36" id="p-36" id="p-36" id="p-36" id="p-36"
id="p-36"
[036] According to some embodiments, the kit is for use in performing a method of the invention. id="p-37" id="p-37" id="p-37" id="p-37" id="p-37" id="p-37" id="p-37"
id="p-37"
[037] According to some embodiments, the PIK3 inhibitor is Alpelisib. id="p-38" id="p-38" id="p-38" id="p-38" id="p-38" id="p-38" id="p-38"
id="p-38"
[038] Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS id="p-39" id="p-39" id="p-39" id="p-39" id="p-39" id="p-39" id="p-39"
id="p-39"
[039] Figure 1: A sequencing chromatogram demonstrating PIK3CA:chr3:Intron 4:179203524:G:C (intron 4:G:C) mutated and non-mutated clone of A549 cells. The G to C mutation is highlighted in a circle. id="p-40" id="p-40" id="p-40" id="p-40" id="p-40" id="p-40" id="p-40"
id="p-40"
[040] Figure 2: A bar graph showing normalized RNA levels of intron 4:G:C mutated clone compared to the non-mutated clone of A549 cells. id="p-41" id="p-41" id="p-41" id="p-41" id="p-41" id="p-41" id="p-41"
id="p-41"
[041] Figure 3: A line graph exhibiting the proliferation rate of intron 4:G:C mutated clone compared to the non-mutated clone of A549 cells. id="p-42" id="p-42" id="p-42" id="p-42" id="p-42" id="p-42" id="p-42"
id="p-42"
[042] Figure 4: A line graph showing the proliferation rate of intron 4:G:C mutated clone compared to the non-mutated clone of A549 cells, in the presence, or the absence, of Alpelisib drug.
DETAILED DESCRIPTION OF THE INVENTION id="p-43" id="p-43" id="p-43" id="p-43" id="p-43" id="p-43" id="p-43"
id="p-43"
[043] The present invention, in some embodiments, provides methods of detecting oncogenic phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), diagnosing cancer and determining suitability of a subject suffering from cancer to be treated with a PI3K inhibitor comprising detecting the presence of a cytosine at position 179203524 on chromosome 3 of hg38. Nucleic acid molecules and kits that differentiate between a cytosine and a guanine at position 179203524 on chromosome 3 of hg38 are also provided. id="p-44" id="p-44" id="p-44" id="p-44" id="p-44" id="p-44" id="p-44"
id="p-44"
[044] By a first aspect, there is provided a method of detecting phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), the method comprising detecting the presence of a cytosine at position 179203524 on chromosome 3, thereby detecting PIK3CA. id="p-45" id="p-45" id="p-45" id="p-45" id="p-45" id="p-45" id="p-45"
id="p-45"
[045] By another aspect, there is provided a method of diagnosing cancer in a subject, the method comprising detecting the presence of a cytosine at position 179203524 on chromosome 3 in the subject, thereby diagnosing cancer in a subject. id="p-46" id="p-46" id="p-46" id="p-46" id="p-46" id="p-46" id="p-46"
id="p-46"
[046] By another aspect, there is provided a method of selecting a subject suitable for treatment with a phospatidylinositol-3 kinase (PI3K) inhibitor, the method comprising detecting the presence of a cytosine at position 179203524 on chromosome 3 in the subject, thereby selecting a subject suitable for treatment with a PI3K inhibitor. id="p-47" id="p-47" id="p-47" id="p-47" id="p-47" id="p-47" id="p-47"
id="p-47"
[047] In some embodiments, the PIK3CA is oncogenic PIK3CA. In some embodiments, the PIK3CA is mutant PIK3CA. In some embodiments, the PIK3CA is a cancer driver. In some embodiments, the method is a method of detecting oncogenic PIK3CA. id="p-48" id="p-48" id="p-48" id="p-48" id="p-48" id="p-48" id="p-48"
id="p-48"
[048] In some embodiments, the method is an in vitro method. In some embodiments, the method is an ex vivo method. In some embodiments, the method is a diagnostic method. In some embodiments, the method is a prognostic method. In some embodiments, the method is a method of detecting cancer. In some embodiments, the method is a method of detecting an oncogene. In some embodiments, the method is a method of detecting an oncogenic mutation. In some embodiments, the method is a method of detecting a potential oncogene. In some embodiments, the method is a method of detecting a potential oncogenic mutation. In some embodiments, the method is a method of selecting a patient population. In some embodiments, the patient population is a population suitable for treatment. In some embodiments, treatment is treatment with a PI3K inhibitor. id="p-49" id="p-49" id="p-49" id="p-49" id="p-49" id="p-49" id="p-49"
id="p-49"
[049] In some embodiments, the subject is a mammal. In some embodiments, the mammal is a human. In some embodiments, the subject is in need of a method of the invention. In some embodiments, the subject is suspected of suffering from cancer. In some embodiments, the subject suffers from cancer. In some embodiments, the subject is naïve to treatment. In some embodiments, the subject has already received an anticancer treatment. In some embodiments, the anticancer treatment does not comprise a PI3K inhibitor. In some embodiments, the subject is in need of treatment. In some embodiments, the subject was not previously determined to have a mutation in PIK3CA. In some embodiments, a mutation in PIK3CA is a mutation in the coding region of PIK3CA. In some embodiments, the mutation in the coding region is a non-synonymous mutation. id="p-50" id="p-50" id="p-50" id="p-50" id="p-50" id="p-50" id="p-50"
id="p-50"
[050] In some embodiments, the method comprises receiving a sample. In some embodiments, the method comprises obtaining a sample. In some embodiments, the sample is from the subject. In some embodiments, the sample comprises a cell. In some embodiments, the sample comprises a nucleic acid molecule. In some embodiments, the cell is from the subject. In some embodiments, the nucleic acid molecule is from the subject. In some embodiments, the cell is a cancerous cell. In some embodiments, the cell is at risk of being a cancerous cell. In some embodiments, the sample is a tumor sample. In some embodiments, the tumor sample is a biopsy. In some embodiments, the biopsy comprises at least one cancerous cell. In some embodiments, the sample comprises a plurality of nucleic acid molecules. In some embodiments, the sample comprises at least one nucleic acid molecule derived from a cancer cell. In some embodiments, the cancer cell is a cancer cell of the subject. In some embodiments, the sample is a blood sample. In some embodiments, the sample is a bodily fluid sample. In some embodiments, the bodily fluid is selected from at least one of: blood, serum, plasma, gastric fluid, intestinal fluid, saliva, bile, tumor fluid, lymph, breast milk, urine, interstitial fluid, vaginal fluid, cerebral spinal fluid and stool. In some embodiments, the bodily fluid is tumor fluid. In some embodiments, the biopsy is a liquid biopsy. In some embodiments, the liquid biopsy comprises at least one cell free DNA (cfDNA) molecule. In some embodiments, the at least one cfDNA molecule is derived from a cancerous cell. id="p-51" id="p-51" id="p-51" id="p-51" id="p-51" id="p-51" id="p-51"
id="p-51"
[051] In some embodiments, the detecting is in the sample. In some embodiments, the detecting is in the nucleic acid molecule. In some embodiments, the detecting is in the cell. In some embodiments, detecting comprises amplifying the nucleic acid molecule. In some embodiments, detecting comprises PCR. In some embodiments, detecting comprises sequencing. In some embodiments, sequencing is whole genome sequencing. In some embodiments, sequencing is next generation sequencing. In some embodiments, sequencing is massively parallel sequencing. In some embodiments, the detecting is with a molecule of the invention. In some embodiments, the detecting is with a nucleic acid molecule that is specific to a cytosine at position 179203524 on chromosome 3. In some embodiments, specific comprises not binding to a non-cytosine at position 179203524. In some embodiments, specific comprises not binding to quinine at position 179203524. In some embodiments, the molecule is a primer. In some embodiments, the primer binds to a molecule comprising cytosine at position 179203524 on chromosome 3 and does not bind to a molecule not comprising a cytosine at position 179203524 on chromosome 3. In some embodiments, not comprising a cytosine is comprising a guanine. In some embodiments, the primer amplifies a molecule comprising a cytosine at position 179203524 on chromosome 3. In some embodiments, the primer does not amplify a molecule not comprising a cytosine at position 179203524 on chromosome 3. In some embodiments, the molecule is a probe. In some embodiments, the probe hybridizes to a molecule comprising cytosine at position 179203524 on chromosome 3 and does not hybridize to a molecule not comprising a cytosine at position 179203524 on chromosome 3. In some embodiments, the probe is integrated when amplifying a molecule comprising a cytosine at position 179203524 on chromosome 3. In some embodiments, the probe is not integrated when amplifying a molecule not comprising a cytosine at position 179203524 on chromosome 3. id="p-52" id="p-52" id="p-52" id="p-52" id="p-52" id="p-52" id="p-52"
id="p-52"
[052] In some embodiments, the nucleic acid molecule comprises or consists of not more than 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 nucleotides. Each possibility represents a separate embodiment of the invention. In some embodiments, the nucleic acid molecule comprises or consists of not more than 25 nucleotides. In some embodiments, the nucleic acid molecule comprises or consists of not more than 50 nucleotides. In some embodiments, the nucleic acid molecule comprises or consists of at least 5, 8, 10, 12, 15, 18, 20, 25, 30, 35, 40, 45 or 50 nucleotides. Each possibility represents a separate embodiment of the invention. In some embodiments, the nucleic acid molecule comprises or consists of at least 8 nucleotides. In some embodiments, the nucleic acid molecule comprises or consists of at least 12 nucleotides. In some embodiments, the nucleic acid molecule comprises or consists of at least 20 nucleotides. id="p-53" id="p-53" id="p-53" id="p-53" id="p-53" id="p-53" id="p-53"
id="p-53"
[053] In some embodiments, the molecule is a nucleic acid molecule. The term "nucleic acid" is well known in the art. A "nucleic acid" as used herein will generally refer to a molecule (i.e., a strand) of DNA, RNA or a derivative or analog thereof, comprising a nucleobase. A nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (e.g., an adenine "A," a guanine "G," a thymine "T" or a cytosine "C") or RNA (e.g., an A, a G, an uracil "U" or a C). id="p-54" id="p-54" id="p-54" id="p-54" id="p-54" id="p-54" id="p-54"
id="p-54"
[054] The terms "nucleic acid molecule" include but not limited to single-stranded RNA (ssRNA), double-stranded RNA (dsRNA), single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), small RNA such as miRNA, siRNA and other short interfering nucleic acids, snoRNAs, snRNAs, tRNA, piRNA, tnRNA, small rRNA, hnRNA, circulating nucleic acids, fragments of genomic DNA or RNA, degraded nucleic acids, ribozymes, viral RNA or DNA, nucleic acids of infectious origin, amplification products, modified nucleic acids, plasmidical or organellar nucleic acids and artificial nucleic acids such as oligonucleotides. id="p-55" id="p-55" id="p-55" id="p-55" id="p-55" id="p-55" id="p-55"
id="p-55"
[055] In some embodiments, the nucleic acid molecule is a DNA molecule. In some embodiments, the DNA is genomic DNA. In some embodiments, the DNA is cfDNA. In some embodiments, the DNA molecule comprises a PIK3CA genomic locus. In some embodiments, the DNA molecule comprises a PIK3CA gene. In some embodiments, the DNA molecule comprises a portion or fragment of a PIK3CA genomic locus. In some embodiments, the DNA molecule comprises a portion or fragment of the PIK3CA gene. In some embodiments, the portion or fragment comprises position 179203524 on chromosome 3. In some embodiments, the nucleic acid molecule is a pre-mRNA molecule. In some embodiments, the pre-mRNA is a pre-mRNA of PIK3CA. In some embodiments, the pre-mRNA is before splicing. In some embodiments, the nucleic acid molecule comprises introns. id="p-56" id="p-56" id="p-56" id="p-56" id="p-56" id="p-56" id="p-56"
id="p-56"
[056] In some embodiments, the PIK3CA gene comprises SEQ ID NO: 1. In some embodiments, the PIK3CA gene consists of SEQ ID NO: 1. In some embodiments, the PIK3CA pre-mRNA transcript comprises SEQ ID NO: 1. In some embodiments, the PIK3CA pre-mRNA transcript consists of SEQ ID NO: 1. In some embodiments, SEQ ID NO: 1 is transcript ENST00000263967.4. In some embodiments, mutation is mutation of the guanine at position 179203524 on chromosome 3 to cytosine. In some embodiments, position 179203524 on chromosome 3 is position 55168 in the nucleotide sequence as set forth in SEQ ID NO: 1. In some embodiments, a cytosine at position 179203524 on chromosome 3 is a cytosine at position 55168 of SEQ ID NO: 1. In some embodiments, a cytosine at position 55168 is mutation of the guanine at position 55168 to cytosine. id="p-57" id="p-57" id="p-57" id="p-57" id="p-57" id="p-57" id="p-57"
id="p-57"
[057] In some embodiments, the PIK3CA gene comprises SEQ ID NO: 2. In some embodiments, the PIK3CA gene consists of SEQ ID NO: 2. In some embodiments, the PIK3CA pre-mRNA transcript comprises SEQ ID NO: 2. In some embodiments, the PIK3CA pre-mRNA transcript consists of SEQ ID NO: 2. In some embodiments, mutation is mutation of the guanine at position 179203524 on chromosome 3 to cytosine. In some embodiments, position 179203524 on chromosome 3 is position 54951 in the nucleotide sequence as set forth in SEQ ID NO: 1. In some embodiments, a cytosine at position 179203524 on chromosome 3 is a cytosine at position 54951 of SEQ ID NO: 2. In some embodiments, a cytosine at position 54951 is mutation of the guanine at position 54951 to cytosine. In some embodiments, the cytosine is within intron 4 of PIK3CA. In some embodiments, intron 4 of PIK3CA comprises SEQ ID NO: 3. In some embodiments, intron of PIK3CA consists of SEQ ID NO: 3. In some embodiments, position 179203524 on chromosome 3 is position 1984 in the nucleotide sequence as set forth in SEQ ID NO: 3. In some embodiments, a cytosine at position 1984 is mutation of the guanine at position 19to cytosine. id="p-58" id="p-58" id="p-58" id="p-58" id="p-58" id="p-58" id="p-58"
id="p-58"
[058] In some embodiments, chromosome 3 is with respect to the human genome. In some embodiments, chromosome 3 is with respect to human genome build hg38. In some embodiments, position 179203524 on chromosome 3 is with respect to human genome build hg38. id="p-59" id="p-59" id="p-59" id="p-59" id="p-59" id="p-59" id="p-59"
id="p-59"
[059] In some embodiments, the presence of the cytosine indicates the presence of oncogenic PIK3CA. In some embodiments, the presence of the cytosine indicates the PIK3CA is oncogenic. In some embodiments, the presence of the cytosine indicates the subject suffers from cancer. In some embodiments, the presence of the cytosine diagnoses the subject with cancer. In some embodiments, the presence of the cytosine indicates the subject is suitable to be treated with a PIK3 inhibitor. In some embodiments, the absence of the cytosine indicates the PIK3CA is non-oncogenic. In some embodiments, the absence of the cytosine indicates the subject does not suffer from cancer. In some embodiments, the absence of the cytosine indicates the subject is not suitable to be treated with a PIKinhibitor. id="p-60" id="p-60" id="p-60" id="p-60" id="p-60" id="p-60" id="p-60"
id="p-60"
[060] As used herein "cancer" or "pre-malignancy" are diseases associated with cell proliferation. Non-limiting types of cancer include carcinoma, sarcoma, lymphoma, leukemia, blastoma and germ cells tumors. In some embodiments, cancer is a solid cancer. In some embodiments, cancer is a hematopoietic cancer. In some embodiments, cancer is a tumor. In some embodiments, the cancer is selected from hepato-biliary cancer, cervical cancer, urogenital cancer (e.g., urothelial cancer), testicular cancer, prostate cancer, thyroid cancer, ovarian cancer, nervous system cancer, ocular cancer, lung cancer, soft tissue cancer, bone cancer, pancreatic cancer, bladder cancer, skin cancer, intestinal cancer, hepatic cancer, rectal cancer, colorectal cancer, esophageal cancer, gastric cancer, gastroesophageal cancer, breast cancer (e.g., triple negative breast cancer), renal cancer (e.g., renal carcinoma), skin cancer, head and neck cancer, leukemia and lymphoma. In some embodiments, the cancer is selected from: breast cancer, lung cancer, uterine cancer, brain cancer, head and neck cancer, kidney cancer, and thyroid cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is lung cancer. In some embodiments, the breast cancer is breast invasive carcinoma. In some embodiments, the lung cancer is lung squamous cell carcinoma. id="p-61" id="p-61" id="p-61" id="p-61" id="p-61" id="p-61" id="p-61"
id="p-61"
[061] In some embodiments, the method further comprises administering at least one anticancer therapy to a subject diagnosed with cancer. In some embodiments, the method further comprises administering at least one PIK3 inhibitor to a subject determined to be suitable. In some embodiments, the anticancer therapy is a PIK3 inhibitor. In some embodiments, the administering is after the detecting. Anticancer therapies are well known in the art and any such therapy may be used. These include, but are not limited to radiation therapy, surgery, chemotherapy, immunotherapy, and targeted therapy. In some embodiments, the immunotherapy is immune checkpoint blockade/inhibition. In some embodiments, the immunotherapy is adoptive cell therapy or CAR therapy. id="p-62" id="p-62" id="p-62" id="p-62" id="p-62" id="p-62" id="p-62"
id="p-62"
[062] As used herein, the terms "administering," "administration," and like terms refer to any method which, in sound medical practice, delivers a composition containing an active agent to a subject in such a manner as to provide a therapeutic effect. One aspect of the present subject matter provides for intravenous administration of a therapeutically effective amount of a composition of the present subject matter to a patient in need thereof. Other suitable routes of administration can include parenteral, oral, intravenous, intramuscular, or intraperitoneal. id="p-63" id="p-63" id="p-63" id="p-63" id="p-63" id="p-63" id="p-63"
id="p-63"
[063] The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. id="p-64" id="p-64" id="p-64" id="p-64" id="p-64" id="p-64" id="p-64"
id="p-64"
[064] In some embodiments, the PIK3 inhibitor is a small molecule inhibitor. In some embodiments, the PIK3 inhibitor is nucleic acid molecule. In some embodiments, the nucleic acid molecule is an antisense molecule. In some embodiments, the nucleic acid molecule is reverse complementary to PIK3. In some embodiments, the nucleic acid molecule is selected from a small interfering RNA (siRNA), a small hairpin RNA (shRNA), an antisense oligonucleotide (ASO) and a gapmer. In some embodiments, the PIK3 inhibitor is an inhibitor of the catalytic subunit of PIK3. In some embodiments, the catalytic subunit is P110. In some embodiments, the PIK3 inhibitor is specific to PIK3. In some embodiments, the PIK3 inhibitor is a P110 specific inhibitor. In some embodiments, P110 is P110 isoform alpha (P110α). In some embodiments, the PIK3 inhibitor is Alpelisib. Examples of PIKinhibitors include, but are not limited to Alpelisib, Inavolisib, Risovalisib, Serabelisib, Copanlisib, RLY-2608, HS-10352, BPI-21668, Taselisib, TQ-B3525, MEN1611, Paxalisib, Gedatolisib, Ipatasertib, Capivasertib, and Miransertib. id="p-65" id="p-65" id="p-65" id="p-65" id="p-65" id="p-65" id="p-65"
id="p-65"
[065] In some embodiments, a composition is administered. In some embodiments, the composition comprises a PIK3 inhibitor. In some embodiments, the composition comprises a nucleic acid molecule of the invention. In some embodiments, the composition comprises a therapeutically effective amount of the PIK3 inhibitor. In some embodiments, the composition is a diagnostic composition. In some embodiments, the composition is a therapeutic composition. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the composition further comprises a pharmaceutically acceptable carrier, excipient or adjuvant. id="p-66" id="p-66" id="p-66" id="p-66" id="p-66" id="p-66" id="p-66"
id="p-66"
[066] As used herein, the term "carrier," "excipient," or "adjuvant" refers to any component of a pharmaceutical composition that is not the active agent. As used herein, the term "pharmaceutically acceptable carrier" refers to non-toxic, inert solid, semi-solid liquid filler, diluent, encapsulating material, formulation auxiliary of any type, or simply a sterile aqueous medium, such as saline. Some examples of the materials that can serve as pharmaceutically acceptable carriers are sugars, such as lactose, glucose and sucrose, starches such as corn starch and potato starch, cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt, gelatin, talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol, polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate, agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline, Ringer's solution; ethyl alcohol and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations. Some non-limiting examples of substances which can serve as a carrier herein include sugar, starch, cellulose and its derivatives, powered tragacanth, malt, gelatin, talc, stearic acid, magnesium stearate, calcium sulfate, vegetable oils, polyols, alginic acid, pyrogen-free water, isotonic saline, phosphate buffer solutions, cocoa butter (suppository base), emulsifier as well as other non-toxic pharmaceutically compatible substances used in other pharmaceutical formulations. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, excipients, stabilizers, antioxidants, and preservatives may also be present. Any non-toxic, inert, and effective carrier may be used to formulate the compositions contemplated herein. Suitable pharmaceutically acceptable carriers, excipients, and diluents in this regard are well known to those of skill in the art, such as those described in The Merck Index, Thirteenth Edition, Budavari et al., Eds., Merck & Co., Inc., Rahway, N.J. (2001); the CTFA (Cosmetic, Toiletry, and Fragrance Association) International Cosmetic Ingredient Dictionary and Handbook, Tenth Edition (2004); and the "Inactive Ingredient Guide," U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Management, the contents of all of which are hereby incorporated by reference in their entirety. Examples of pharmaceutically acceptable excipients, carriers and diluents useful in the present compositions include distilled water, physiological saline, Ringer's solution, dextrose solution, Hank's solution, and DMSO. These additional inactive components, as well as effective formulations and administration procedures, are well known in the art and are described in standard textbooks, such as Goodman and Gillman’s: The Pharmacological Bases of Therapeutics, 8th Ed., Gilman et al. Eds. Pergamon Press (1990); Remington’s Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, Pa. (1990); and Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins, Philadelphia, Pa., (2005), each of which is incorporated by reference herein in its entirety. The presently described composition may also be contained in artificially created structures such as liposomes, ISCOMS, slow-releasing particles, and other vehicles which increase the half-life of the peptides or polypeptides in serum. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. Liposomes for use with the presently described peptides are formed from standard vesicle-forming lipids which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally determined by considerations such as liposome size and stability in the blood. A variety of methods are available for preparing liposomes as reviewed, for example, by Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York, and see also U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369. id="p-67" id="p-67" id="p-67" id="p-67" id="p-67" id="p-67" id="p-67"
id="p-67"
[067] The carrier may comprise, in total, from about 0.1% to about 99.99999% by weight of the pharmaceutical compositions presented herein. id="p-68" id="p-68" id="p-68" id="p-68" id="p-68" id="p-68" id="p-68"
id="p-68"
[068] By another aspect, there is provided a PIK3 inhibitor for use in treating cancer in a subject in need thereof. id="p-69" id="p-69" id="p-69" id="p-69" id="p-69" id="p-69" id="p-69"
id="p-69"
[069] In some embodiments, the subject has been determined to comprise a cytosine at position 179203524 on chromosome 3. In some embodiments, the subject has been determined by a method of the invention. In some embodiments, the subject has been determined to comprise a nucleic acid molecule comprising a cytosine at position 1792035on chromosome 3. In some embodiments, a cell of the subject has been determined to comprise a nucleic acid molecule comprising a cytosine at position 179203524 on chromosome 3. In some embodiments, the cell is a cancerous cell. In some embodiments, a cancer of the subject has been determined to comprise a nucleic acid molecule comprising a cytosine at position 179203524 on chromosome 3. In some embodiments, the determining is within a sample from the cancer. In some embodiments, the determining is within a liquid biopsy from the subject. id="p-70" id="p-70" id="p-70" id="p-70" id="p-70" id="p-70" id="p-70"
id="p-70"
[070] By another aspect, there is provided a nucleic acid molecule that differentiates between a cytosine and a guanine at position 179203524 on chromosome 3. id="p-71" id="p-71" id="p-71" id="p-71" id="p-71" id="p-71" id="p-71"
id="p-71"
[071] In some embodiments, the nucleic acid molecule does not bind to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule does not bind to a nucleotide sequence present in SEQ ID NO: 1. In some embodiments, the nucleic acid molecule does not bind to a nucleotide sequence as set forth in SEQ ID NO: 1. In some embodiments, the nucleic acid molecule does not bind to SEQ ID NO: 2. In some embodiments, the nucleic acid molecule does not bind to a nucleotide sequence present in SEQ ID NO: 2. In some embodiments, the nucleic acid molecule does not bind to a nucleotide sequence as set forth in SEQ ID NO: 2. In some embodiments, the nucleic acid molecule does not bind to SEQ ID NO: 3. In some embodiments, the nucleic acid molecule does not bind to a nucleotide sequence present in SEQ ID NO: 3. In some embodiments, the nucleic acid molecule does not bind to a nucleotide sequence as set forth in SEQ ID NO: 3. id="p-72" id="p-72" id="p-72" id="p-72" id="p-72" id="p-72" id="p-72"
id="p-72"
[072] In some embodiments, the nucleic acid molecule does bind to SEQ ID NO: 4. In some embodiments, the nucleic acid molecule does bind to a nucleotide sequence present in SEQ ID NO: 4. In some embodiments, the nucleic acid molecule does bind to a nucleotide sequence as set forth in SEQ ID NO: 4. In some embodiments, the nucleic acid molecule does bind to SEQ ID NO: 5. In some embodiments, the nucleic acid molecule does bind to a nucleotide sequence present in SEQ ID NO: 5. In some embodiments, the nucleic acid molecule does bind to a nucleotide sequence as set forth in SEQ ID NO: 5. In some embodiments, the nucleic acid molecule does bind to SEQ ID NO: 6. In some embodiments, the nucleic acid molecule does bind to a nucleotide sequence present in SEQ ID NO: 6. In some embodiments, the nucleic acid molecule does bind to a nucleotide sequence as set forth in SEQ ID NO: 6. id="p-73" id="p-73" id="p-73" id="p-73" id="p-73" id="p-73" id="p-73"
id="p-73"
[073] In some embodiments, the nucleic acid molecule is a primer. In some embodiments, the nucleic acid molecule is a probe. In some embodiments, the nucleic acid molecule is reverse complementary to SEQ ID NO: 4. In some embodiments, the nucleic acid molecule is reverse complementary to SEQ ID NO: 5. In some embodiments, the nucleic acid molecule is reverse complementary to SEQ ID NO: 6. In some embodiments, the nucleic acid molecule comprises ggctcc. In some embodiments, the nucleic acid molecule comprises atggctcc. In some embodiments, the nucleic acid molecule comprises aaatggctcc (SEQ ID NO: 7). In some embodiments, the nucleic acid molecule comprises aggggg. In some embodiments, the nucleic acid molecule comprises attaaggggg (SEQ ID NO: 8). id="p-74" id="p-74" id="p-74" id="p-74" id="p-74" id="p-74" id="p-74"
id="p-74"
[074] In some embodiments, the nucleic acid molecule is for use in performing a method of the invention. In some embodiments, the nucleic acid molecule is for use in diagnosing cancer. In some embodiments, the nucleic acid molecule is for use in determining suitability of a subject. In some embodiments, the nucleic acid molecule is for use in identifying oncogenic PIK3CA. id="p-75" id="p-75" id="p-75" id="p-75" id="p-75" id="p-75" id="p-75"
id="p-75"
[075] By another aspect, there is provide a kit comprising a nucleic acid molecule of the invention. id="p-76" id="p-76" id="p-76" id="p-76" id="p-76" id="p-76" id="p-76"
id="p-76"
[076] By another aspect, there is provided a kit comprising a PIK3 inhibitor. id="p-77" id="p-77" id="p-77" id="p-77" id="p-77" id="p-77" id="p-77"
id="p-77"
[077] In some embodiments, the kit comprises instructions for performing a method of the invention. In some embodiments, the kit further comprises a PIK3 inhibitor. In some embodiments, the kit further comprises a nucleic acid molecule of the invention. In some embodiments, the kit is for use in a method of the invention. id="p-78" id="p-78" id="p-78" id="p-78" id="p-78" id="p-78" id="p-78"
id="p-78"
[078] As used herein, the term "about" when combined with a value refers to plus and minus 10% of the reference value. For example, a length of about 1000 nanometers (nm) refers to a length of 1000 nm+- 100 nm. id="p-79" id="p-79" id="p-79" id="p-79" id="p-79" id="p-79" id="p-79"
id="p-79"
[079] It is noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a polynucleotide" includes a plurality of such polynucleotides and reference to "the polypeptide" includes reference to one or more polypeptides and equivalents thereof known to those skilled in the art, and so forth. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements, or use of a "negative" limitation. id="p-80" id="p-80" id="p-80" id="p-80" id="p-80" id="p-80" id="p-80"
id="p-80"
[080] In those instances where a convention analogous to "at least one of A, B, and C, etc." is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., "a system having at least one of A, B, and C" would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase "A or B" will be understood to include the possibilities of "A" or "B" or "A and B." id="p-81" id="p-81" id="p-81" id="p-81" id="p-81" id="p-81" id="p-81"
id="p-81"
[081] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments pertaining to the invention are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations of the various embodiments and elements thereof are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein. id="p-82" id="p-82" id="p-82" id="p-82" id="p-82" id="p-82" id="p-82"
id="p-82"
[082] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents, unless the context clearly dictates otherwise. The terms "a" (or "an") as well as the terms "one or more" and "at least one" can be used interchangeably. id="p-83" id="p-83" id="p-83" id="p-83" id="p-83" id="p-83" id="p-83"
id="p-83"
[083] Furthermore, "and/or" is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and/or" as used in a phrase such as "A and/or B" is intended to include A and B, A or B, A (alone), and B (alone). Likewise, the term "and/or" as used in a phrase such as "A, B, and/or C" is intended to include A, B, and C; A, B, or C; A or B; A or C; B or C; A and B; A and C; B and C; A (alone); B (alone); and C (alone). id="p-84" id="p-84" id="p-84" id="p-84" id="p-84" id="p-84" id="p-84"
id="p-84"
[084] Wherever embodiments are described with the language "comprising," otherwise analogous embodiments described in terms of "consisting of" and/or "consisting essentially of" are included. id="p-85" id="p-85" id="p-85" id="p-85" id="p-85" id="p-85" id="p-85"
id="p-85"
[085] Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples. id="p-86" id="p-86" id="p-86" id="p-86" id="p-86" id="p-86" id="p-86"
id="p-86"
[086] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
EXAMPLES id="p-87" id="p-87" id="p-87" id="p-87" id="p-87" id="p-87" id="p-87"
id="p-87"
[087] Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I- III Cellis, J. E., ed. (1994); "Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley-Liss, N. Y. (1994), Third Edition; "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference. Other general references are provided throughout this document.
EXAMPLE 1: Discovery of a new mutation in the human PIK3CA gene id="p-88" id="p-88" id="p-88" id="p-88" id="p-88" id="p-88" id="p-88"
id="p-88"
[088] A mutation in the fourth intron of PIK3CA gene was identified by the inventors. The mutation is located on chromosome 3 at position 179203524, with respect to the hgreference genome. The mutation changes the positive strand reference allele G to the positive strand alternative allele C (e.g., G to C mutation). According to hg38 coordinates, intron is located between position 179201541 and position 179203543. Thus, this mutation is located 19 bps from the 3' terminal side of the fourth intron (there are 19 nucleotides after it in the intron). The mutation is herein designated by the following ID: PIK3CA:chr3:Intron 4:179203524:G:C (or alternatively termed "intron 4:G:C" mutation). id="p-89" id="p-89" id="p-89" id="p-89" id="p-89" id="p-89" id="p-89"
id="p-89"
[089] Table 1 summarizes the exon-intron map of the PIK3CA gene (transcript ENST00000263967.4, SEQ ID NO: 1). The mutation PIK3CA:chr3:Intron 4:179203524:G:C, is in intron 4, which consists of 2003 nucleotides, and is located between exon 4 and exon 5. The G that is mutated is nucleotide 1984 of intron 4 (SEQ ID NO: 3).
Table 1 – Intron-Exon map of isoform 1 of the PIK3CA gene.
Exon / Intron Start End LengthExon 1 179,148,357 179,148,603 2Intron 1 179,148,604 179,198,749 50,1Exon 2 179,198,750 179,199,177 4Intron 2 179,199,178 179,199,689 5Exon 3 179,199,690 179,199,899 2Intron 3 179,199,900 179,201,289 1,3Exon 4 179,201,290 179,201,540 2Intron 4 179,201,541 179,203,543 2,0Exon 5 179,203,544 179,203,789 2Intron 5 179,203,790 179,204,502 7Exon 6 179,204,503 179,204,588 Intron 6 179,204,589 179,209,594 5,0Exon 7 179,209,595 179,209,700 106 Intron 7 179,209,701 179,210,185 4Exon 8 179,210,186 179,210,338 1Intron 8 179,210,339 179,210,430 Exon 9 179,210,431 179,210,565 1Intron 9 179,210,566 179,218,209 7,6Exon 10 179,218,210 179,218,334 1Intron 10 179,218,335 179,219,195 8Exon 11 179,219,196 179,219,277 Intron 11 179,219,278 179,219,570 2Exon 12 179,219,571 179,219,735 1Intron 12 179,219,736 179,219,948 2Exon 13 179,219,949 179,220,052 1Intron 13 179,220,053 179,220,985 9Exon 14 179,220,986 179,221,157 1Intron 14 179,221,158 179,224,080 2,9Exon 15 179,224,081 179,224,187 1Intron 15 179,224,188 179,224,699 5Exon 16 179,224,700 179,224,821 1Intron 16 179,224,822 179,225,961 1,1Exon 17 179,225,962 179,226,040 Intron 17 179,226,041 179,229,271 3,2Exon 18 179,229,272 179,229,442 1Intron 18 179,229,443 179,230,003 5Exon 19 179,230,004 179,230,121 1Intron 19 179,230,122 179,230,224 1Exon 20 179,230,225 179,230,376 1Intron 20 179,230,377 179,234,093 3,7Exon 21 179,234,094 179,240,093 6,0 EXAMPLE 2: The in vitro effect of the intron 4:g:c mutation id="p-90" id="p-90" id="p-90" id="p-90" id="p-90" id="p-90" id="p-90"
id="p-90"
[090] The intron 4:g:c mutation being in an intron does not directly alter the amino acid sequence of the PIK3CA protein. Further, the mutation is not predicted to alter a splice site and thus generate a mis-spliced protein. Rather, the mutation was computationally predicted to increase transcription of the PIK3CA pre-mRNA. In order to investigate the effect of the PIK3CA:chr3:Intron 4:179203524:G:C mutation, a human lung cancer cell line that has no known mutations in PIK3CA gene was identified using cancer cell line encyclopedia (CCLE) databases, literature and next generation sequencing (NGS) analysis. The A549 cell line (lung cell carcinoma) was edited by CRISPR technology to generate a stable homozygous clone that harbors this point mutation; PIK3CA:chr3:Intron 4:179203524:G:C. id="p-91" id="p-91" id="p-91" id="p-91" id="p-91" id="p-91" id="p-91"
id="p-91"
[091] The sequence of the edited cells was confirmed by PCR and sequenced at the mutated region ( Fig. 1 ). Examination of the level of PIK3CA-transcribed mRNA in A549 edited cells harboring this mutation, by real-time PCR (RTqPCR), revealed ~52% increase compared to A549 cells that went through the identical CRISPR process and were not identified with this mutation, thus served as negative control cells ( Fig. 2 ). This increase correlates with the computational prediction model in which a ~60% increase in mRNA levels was predicted. The primers used for PCR were: Forward-CATGGAGGAGAACCCTTATG (SEQ ID NO: 9) and Reverse-CTTTCGGCCTTTAACAGAGC (SEQ ID NO: 10). id="p-92" id="p-92" id="p-92" id="p-92" id="p-92" id="p-92" id="p-92"
id="p-92"
[092] The next objective was to examine whether this mutation affects cell proliferation. As discussed hereinabove, several oncogenic point mutations in PIK3CA are known and so it was hypothesized that increased expression of the wild-type protein would also be oncogenic. This was examined using a CellTiter-Glo® luminescent cell viability assay. As measured by the assay, there was a ~2.25-fold increase in the proliferation rate of the intron 4:G:C mutated cells, versus the non-mutated cells ( Fig. 3 ). Thus, this mutation is a driver mutation, that increases cell proliferation rate and is oncogenic. id="p-93" id="p-93" id="p-93" id="p-93" id="p-93" id="p-93" id="p-93"
id="p-93"
[093] Alpelisib is an alpha-specific PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, breast cancer patients, that harbor known mutations in exon-coding regions of the PIK3CA gene. Alpelisib is known to inhibit the proliferation of cells harboring these known mutations. id="p-94" id="p-94" id="p-94" id="p-94" id="p-94" id="p-94" id="p-94"
id="p-94"
[094] As demonstrated in Figure 4 , addition of Alpelisib to cultured A549 cells homozygous for the intron 4:G:C mutation, diminished their proliferation rate. This reduction brought cell proliferation down to the level of the non-mutated cells. Thus, this mutation can be utilized as a criterion for selecting patients likely to be responsive to PI3K inhibitors, and specifically to alpha inhibitors, such as Alpelisib. id="p-95" id="p-95" id="p-95" id="p-95" id="p-95" id="p-95" id="p-95"
id="p-95"
[095] PI3Ks are activated by phosphorylation of the 3-hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns) lipids in the plasma membrane. Phosphorylation assays are performed to quantify phosphorylation of PtdIns in the mutated cells as compared to the control cells. Increased phosphorylation of PtdIns lipids, indicating enhanced activity of PIK3CA in the intron 4:G:C mutated A549 cells is observed. Migration assays are also performed to test the migration capacity of the mutated cells versus the control cells. Migration and invasion capacity of the mutated cells is increased as compared to the non-mutated cells, indicating that this mutation increases the metastatic potential of the cells harboring it. Finally, a rodent model is constructed to test the mutation in vivo. Cells harboring the mutation and cells devoid of the mutation are injected into immunocompromised rodents and the growth of the resultant tumors is monitored. Tumor growth is also monitored when Alpelisib or other PI3K inhibitor are also administered. The mutated cells result in larger tumors which respond to the PI3K inhibitors.
EXAMPLE 3: The intron 4:g:c mutation in humans id="p-96" id="p-96" id="p-96" id="p-96" id="p-96" id="p-96" id="p-96"
id="p-96"
[096] It was surprisingly found that although this point mutation is in an intron coding region, it leads to a significant increase in the levels of PIK3CA-transcribed mRNA in vitro. To test if this phenomenon occurs in humans, data obtained from the cancer genome atlas (TCGA), a cancer genomics program that molecularly characterized over 20,000 primary cancer and matched normal samples spanning 33 cancer types, was analyzed for the presence of the intron 4:g:c mutation. id="p-97" id="p-97" id="p-97" id="p-97" id="p-97" id="p-97" id="p-97"
id="p-97"
[097] Firstly, the mutation was indeed found in a wide variety of cancer samples from the database. The mutation was present in 4.9% of breast invasive carcinoma (BRCA) patients, 2.5% of lung squamous cell carcinoma (LUSC) patients, 2.4% of uterine corpus endometrial carcinoma (UCEC) patients, 2.4% of glioblastoma multiforme (GBM) patients, 2.1% of head and neck squamous cell carcinoma (HNSC) patients, 2.2% of kidney renal clear cell carcinoma (KIRC) patients, 0.8% of brain lower grade glioma (LGG) patients, 1.2% of lung adenocarcinoma (LUAD) patients, and 1.0% of thyroid carcinoma (THCA) patients. id="p-98" id="p-98" id="p-98" id="p-98" id="p-98" id="p-98" id="p-98"
id="p-98"
[098] Examination of data from the BRCA patients revealed a 1.2-fold increase in PIKCA mRNA levels in patients with the mutation as compared to patients without (P value < 1x10-). A 1.6-fold increase in PIKCA mRNA levels was observed in LUSC patients with the mutation (P value = 1.0x10-3). These results strongly indicate that the mutation does indeed increase transcription in human cancers. id="p-99" id="p-99" id="p-99" id="p-99" id="p-99" id="p-99" id="p-99"
id="p-99"
[099] It was observed that in some breast invasive carcinoma patients, the intron 4:G:C mutation was found to be simultaneously present with other known mutations in the exon-coding region of PIK3CA. For example, 3 patients were found to have the intron 4:G:C mutation and the E545K mutation; six patients were found to have the intron 4:G:C mutation and the H1047R mutation; three patients were found to have the intron 4:G:C and the E542K mutation; three patients were found to have the intron 4:G:C mutation and the Q546R mutation; and one patient was found to have the intron 4:G:C mutation and the H1047L mutation. id="p-100" id="p-100" id="p-100" id="p-100" id="p-100" id="p-100" id="p-100"
id="p-100"
[0100] In conclusion, it was surprisingly found that a point mutation, in a non-translated region of the PIK3CA gene, has a significant oncogenic potential and induces an augmented cancerous phenotype in the cell harboring it, manifested by enhanced proliferation; a phenotype that is reversed by treatment with a PIK3CA inhibitor. These findings highlight this mutation as a diagnostic and prognostic tool, which can also be used as an onco-personalized selection tool of potential responders to PIK3 inhibitor therapy. id="p-101" id="p-101" id="p-101" id="p-101" id="p-101" id="p-101" id="p-101"
id="p-101"
[0101] Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
Claims (28)
1. CLAIMS:
2. What is claimed is: 1. A method of detecting oncogenic phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in a sample, the method comprising, receiving a sample comprising a nucleic acid molecule and detecting the presence of a cytosine at position 179203524 on chromosome 3 in said nucleic acid molecule wherein said position is with respect to human genome build hg38, wherein the presence of said cytosine indicates the presence of oncogenic PIK3CA, thereby detecting oncogenic PIK3CA. 2. A method of diagnosing cancer in a subject, the method comprising receiving a sample from said subject, detecting the presence of a cytosine at position 179203524 on chromosome 3 in a nucleic acid molecule from said sample wherein said position is with respect to human genome build hg38, wherein the presence of said cytosine indicates the subject suffers from cancer, thereby diagnosing cancer in a subject.
3. A method of selecting a subject suffering from cancer suitable for treatment with a phospatidylinositol-3 kinase (PI3K) inhibitor, the method comprising detecting the presence of a cytosine at position 179203524 on chromosome 3 in a nucleic acid molecule derived from a cancer cell of said subject, wherein said position is with respect to human genome build hg38, thereby selecting a subject suffering from cancer suitable for treatment with a PIK3 inhibitor.
4. The method of any one of claims 1 to 3, wherein said nucleic acid molecule is a DNA molecule or a pre-mRNA molecule.
5. The method of claim 4, wherein said DNA molecule comprises a PIK3CA genomic locus or said pre-mRNA comprises a PIK3CA transcript.
6. The method of any one of claims 1 to 5, wherein a PIK3CA gene and transcript comprises SEQ ID NO: 1 or 2 and wherein said cytosine is at position 55168 in the nucleotide sequence as set forth in SEQ ID NO: 1, or at position 54951 in the nucleotide sequence as set forth in SEQ ID NO: 2.
7. The method of any one of claims 2 to 6, wherein said cancer is selected from: breast cancer, lung cancer, uterine cancer, brain cancer, head and neck cancer, kidney cancer, and thyroid cancer.
8. The method of claim 7, wherein said cancer is breast cancer or lung cancer.
9. The method of claim 8, wherein said breast cancer is breast invasive carcinoma and said lung cancer is lung squamous cell carcinoma.
10. The method of any one of claims 1 to 9, wherein said detecting the presence of a cytosine comprises amplifying said nucleic acid molecule with at least one primer specific to said cytosine at position 179203524, wherein said specific primer does not amplify a nucleic acid molecule with a guanine at position 179203524.
11. The method of any one of claims 1 to 10, wherein said detecting the presence of a cytosine comprises sequencing said nucleic acid molecule or an amplified copy thereof.
12. The method of any one of claims 3 to 11, further comprising before said detecting receiving a sample comprising said nucleic acid molecule derived from a cancer cell of said subject.
13. The method of claim 12, wherein said sample is a tumor sample comprising at least one cancerous cell or a liquid biopsy comprising at least one cell-free DNA molecule derived from a cancerous cell.
14. The method of any one of claims 2 to 13, further comprising after said detecting administering to a subject diagnosed with cancer at least one anticancer therapy.
15. The method of any one of claims 3 to 14, further comprising after said detecting administering to a suitable subject at least one PIK3 inhibitor.
16. The method of claim 15, wherein said PIK3 inhibitor is an inhibitor of the catalytic subunit of PIK3 (P110).
17. The method of claim 16, wherein said PIK3 inhibitor is a P110 specific inhibitor.
18. The method of claim 16 or 17, wherein said P110 is P110 isoform alpha (P110α).
19. The method of any one of claims 15 to 18, wherein said PIK3 inhibitor is Alpelisib.
20. A PIK3 inhibitor for use in treating cancer in a subject in need thereof, wherein said subject has been determined to comprise a cytosine at position 179203524 on chromosome 3, wherein said position is with respect to human genome build hg38.
21. The PIK3 inhibitor of claim 20, wherein said determining comprises receiving a sample from said subject comprising a nucleic acid molecule derived from a cancer cell of said subject and detecting the presence of said cytosine at position 1792035on chromosome 3 in said nucleic acid molecule.
22. A nucleic acid molecule that differentiates between a cytosine and a guanine at position 179203524 on chromosome 3, wherein said position is with respect to human genome build hg38.
23. The nucleic acid molecule of claim 22, wherein said nucleic acid molecule does not bind to a nucleotide sequence as set forth in any one of SEQ ID NO: 1-3 and does bind to a nucleotide sequence as set forth in any one of SEQ ID NO: 4-6.
24. The nucleic acid molecule of claim 22 or 23, consisting of not more than nucleotides.
25. The nucleic acid molecule of any one of claims 22 to 24, for use in performing a method of any one of claims 1 to 19.
26. A kit comprising a nucleic acid molecule of any one of claims 22 to 25 and at least one PIK3 inhibitor.
27. The kit of claim 26, for use in performing a method of any one of claims 15 to 19.
28. The kit of claim 26 or 27, wherein said PIK3 inhibitor is Alpelisib.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL304567A IL304567B2 (en) | 2023-07-18 | 2023-07-18 | Methods of detecting oncogenic pik3ca |
| PCT/IL2024/050707 WO2025017560A1 (en) | 2023-07-18 | 2024-07-18 | Methods of detecting oncogenic pik3ca |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL304567A IL304567B2 (en) | 2023-07-18 | 2023-07-18 | Methods of detecting oncogenic pik3ca |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL304567A IL304567A (en) | 2023-08-01 |
| IL304567B1 IL304567B1 (en) | 2024-03-01 |
| IL304567B2 true IL304567B2 (en) | 2024-07-01 |
Family
ID=90097898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304567A IL304567B2 (en) | 2023-07-18 | 2023-07-18 | Methods of detecting oncogenic pik3ca |
Country Status (2)
| Country | Link |
|---|---|
| IL (1) | IL304567B2 (en) |
| WO (1) | WO2025017560A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150079076A1 (en) * | 2011-12-09 | 2015-03-19 | Roche Molecular Systems | Identification of non-responders to her2 inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201726140A (en) * | 2015-09-17 | 2017-08-01 | 瑞典商阿斯特捷利康公司 | Novel biomarkers and methods of treating cancer |
-
2023
- 2023-07-18 IL IL304567A patent/IL304567B2/en unknown
-
2024
- 2024-07-18 WO PCT/IL2024/050707 patent/WO2025017560A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150079076A1 (en) * | 2011-12-09 | 2015-03-19 | Roche Molecular Systems | Identification of non-responders to her2 inhibitors |
Non-Patent Citations (4)
| Title |
|---|
| ENSEMBL GENOME DATABASE PROJECT, TRANSCRIPT: ENST00000263967.4 PIK3CA-201., 17 July 2023 (2023-07-17) * |
| MADSEN, R. R., CANCER-ASSOCIATED PIK3CA MUTATIONS IN OVERGROWTH DISORDERS., 24 October 2018 (2018-10-24) * |
| TAHER, M. M., SUPRATENTORIAL SPORADIC HEMANGIOBLASTOMA: A CASE REPORT WITH MUTATION PROFILING USING NEXT-GENERATION DNA SEQUENCING., 1 June 2023 (2023-06-01) * |
| ZHANG, H. ET AL., PATIENT-DERIVED XENOGRAFTS OF TRIPLE-NEGATIVE BREAST CANCER REPRODUCE MOLECULAR FEATURES OF PATIENT TUMORS AND RESPOND TO MTOR INHIBITION., 7 April 2014 (2014-04-07) * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025017560A1 (en) | 2025-01-23 |
| IL304567A (en) | 2023-08-01 |
| IL304567B1 (en) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes | |
| Wang et al. | Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes | |
| Metro et al. | Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype | |
| US9187787B2 (en) | Method of diagnosing and treating cancer | |
| Zhou et al. | Overexpression of lncRNA TUG1 alleviates NLRP3 inflammasome-mediated cardiomyocyte pyroptosis through targeting the miR-186-5p/XIAP axis in coronary microembolization-induced myocardial damage | |
| Feng et al. | MicroRNA-155 regulates T cell proliferation through targeting GSK3β in cardiac allograft rejection in a murine transplantation model | |
| Chen et al. | The utility of cerebrospinal fluid–derived cell-free DNA in molecular diagnostics for the PIK3CA-related megalencephaly-capillary malformation (MCAP) syndrome: a case report | |
| WO2023147790A1 (en) | Brain glioma biomarker mlkl gene and use thereof | |
| Mu et al. | Exosomal miR-1228-5p down-regulates DUSP22 to promotes cell proliferation and migration in small cell lung cancer | |
| Shen et al. | Exosomes secreted by metastatic cancer cells promotes epithelial mesenchymal transition in small cell lung carcinoma: the key role of Src/TGF-β1 axis | |
| CN108025017A (en) | MiR-19 conditioning agents and application thereof | |
| IL304567B1 (en) | Methods of detecting oncogenic pik3ca | |
| US20080318241A1 (en) | Methods and Systems for Detecting Antiangiogenesis | |
| Li et al. | Cardiac Injury Regulates Neuroinflammation Through Extracellular Vesicle–Mediated Heart-Brain Crosstalk | |
| CN120060476A (en) | Prostate cancer Olaparib treatment drug resistance marker and application thereof | |
| CN114107492B (en) | Molecular marker for tumor molecular typing and therapeutic drug evaluation, and detection primer and kit thereof | |
| Senhaji et al. | Prevalence of IDH1/2 mutations in different subtypes of glioma in the north-east population of Morocco | |
| Wu et al. | Increase of toll-like receptor 4 but decrease of interleukin-8 mRNA expression among ischemic stroke patients under aspirin treatment | |
| CN112119168A (en) | Method for predicting cancer prognosis risk | |
| JP2024502001A (en) | How to treat rhabdoid tumors | |
| CA3202058A1 (en) | A jmjd6 targeting agent for treating prostate cancer | |
| Evgeniev et al. | 113eP H3K27me3 is a potential biomarker for negative prognosis and low OS in NSCLC | |
| US10160971B2 (en) | Methods of modulating WARS2 | |
| CN114134230B (en) | Application of hsa_circ_0003310 | |
| Lukacova et al. | P11. 11. B Stereotactic radiosurgery for brain metastases; outcome and prognostic factors in patients treated with single-fraction and multiple-fractions |